[go: up one dir, main page]

ECSP16074207A - Pirazinas moduladoras de gpr6 - Google Patents

Pirazinas moduladoras de gpr6

Info

Publication number
ECSP16074207A
ECSP16074207A ECIEPI201674207A ECPI201674207A ECSP16074207A EC SP16074207 A ECSP16074207 A EC SP16074207A EC IEPI201674207 A ECIEPI201674207 A EC IEPI201674207A EC PI201674207 A ECPI201674207 A EC PI201674207A EC SP16074207 A ECSP16074207 A EC SP16074207A
Authority
EC
Ecuador
Prior art keywords
gpr6
pirazines
modulating
compounds
modulators
Prior art date
Application number
ECIEPI201674207A
Other languages
English (en)
Inventor
Huikai Sun
Colombia Ldta Anasac
Holly Reichard
Maria Hopkins
Shota Kikuchi
Stephen Hitchcock
Jason Brown
Philippe De Rothschild Maipo Chile Spa Baron
Holger Monenschein
Original Assignee
Eh Europe Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eh Europe Gmbh filed Critical Eh Europe Gmbh
Publication of ECSP16074207A publication Critical patent/ECSP16074207A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C07D241/28—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona compuestos de fórmula (I) que son útiles como moduladores de GPR6, composiciones farmacéuticas de los mismos, métodos para el tratamiento de afecciones asociadas con GPR6, procesos para producir los compuestos y productos intermedios de los mismos.
ECIEPI201674207A 2014-02-14 2016-09-14 Pirazinas moduladoras de gpr6 ECSP16074207A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461940294P 2014-02-14 2014-02-14

Publications (1)

Publication Number Publication Date
ECSP16074207A true ECSP16074207A (es) 2017-09-29

Family

ID=52598823

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201674207A ECSP16074207A (es) 2014-02-14 2016-09-14 Pirazinas moduladoras de gpr6

Country Status (24)

Country Link
US (2) US10000468B2 (es)
EP (1) EP3105216B1 (es)
JP (1) JP6484640B2 (es)
KR (1) KR20160122215A (es)
CN (1) CN106103421B (es)
AU (1) AU2015218402B2 (es)
BR (1) BR112016018418A2 (es)
CA (1) CA2939382A1 (es)
CL (1) CL2016002043A1 (es)
CR (1) CR20160428A (es)
DO (1) DOP2016000211A (es)
EA (1) EA033861B1 (es)
EC (1) ECSP16074207A (es)
ES (1) ES2702205T3 (es)
GE (2) GEAP201814266A (es)
IL (1) IL247140B (es)
MA (1) MA39337B1 (es)
MX (1) MX369857B (es)
MY (1) MY184366A (es)
PE (1) PE20170245A1 (es)
PH (1) PH12016501613B1 (es)
UA (1) UA117779C2 (es)
WO (1) WO2015123533A1 (es)
ZA (1) ZA201606077B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA39337B1 (fr) * 2014-02-14 2019-11-29 Takeda Pharmaceuticals Co Modulateurs de pyrazines de gpr6
KR20210019607A (ko) 2016-06-07 2021-02-22 자코바이오 파마슈티칼스 컴퍼니 리미티드 Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
NZ758458A (en) 2017-03-23 2022-07-29 Jacobio Pharmaceuticals Co Ltd Novel heterocyclic derivatives useful as shp2 inhibitors
CN110520127B (zh) * 2017-03-26 2023-05-16 武田药品工业株式会社 作为gpr6的调节剂的经哌啶基取代的杂芳族羧酰胺和经哌嗪基取代的杂芳族羧酰胺
JOP20180057A1 (ar) 2017-06-15 2019-01-30 Takeda Pharmaceuticals Co مركبات رابع هيدروبيريدو بيرازين والتي تعمل كمعدلات gpr6
US20210393623A1 (en) 2018-09-26 2021-12-23 Jacobio Pharmaceuticals Co., Ltd. Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors
CN115996908A (zh) * 2020-04-30 2023-04-21 俄勒冈健康科学大学 Gpr39蛋白的拮抗剂

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4159331A (en) * 1978-05-05 1979-06-26 The Upjohn Company Antihypertensive 4-aminoquinolines
US5563142A (en) * 1989-12-28 1996-10-08 The Upjohn Company Diaromatic substituted compounds as anti-HIV-1 agents
CN1364167A (zh) * 1999-02-26 2002-08-14 阿瑞那制药公司 G蛋白偶联受体6的小分子调节剂
US6774138B2 (en) 1999-08-31 2004-08-10 Merck & Co., Inc. Thiazolyl(pyridyl)ethyne compounds
DE60114153T2 (de) 2000-02-16 2006-07-06 Neurogen Corp., Branford Substituierte arylpyrazine
EP1397351B1 (en) * 2001-06-01 2009-11-11 F. Hoffmann-La Roche Ag Pyrimidine, triazine and pyrazine derivatives as glutamate receptors
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
PL220783B1 (pl) 2002-03-13 2016-01-29 Janssen Pharmaceutica Nv Pochodna sulfonylowa, jej zastosowanie i sposób wytwarzania oraz kompozycja farmaceutyczna
JPWO2004054617A1 (ja) * 2002-12-13 2006-04-20 協和醗酵工業株式会社 中枢疾患の予防および／または治療剤
ES2377406T3 (es) 2003-07-30 2012-03-27 Xenon Pharmaceuticals Inc. Derivados de la piperazina y su uso como agentes terapéuticos
US20050070718A1 (en) * 2003-09-30 2005-03-31 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
US8580842B2 (en) * 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
EP1715867A4 (en) 2004-02-12 2009-04-15 Merck & Co Inc BIPYRIDYLAMIDE AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5
CA2561831A1 (en) 2004-04-13 2005-12-22 Icagen, Inc. Polycyclic pyrazines as potassium ion channel modulators
GB0414438D0 (en) * 2004-06-28 2004-07-28 Syngenta Participations Ag Chemical compounds
US20060199828A1 (en) 2005-03-04 2006-09-07 Georg Jaeschke Pyrazine-2-carboxyamide derivatives
RU2007146444A (ru) 2005-05-13 2009-06-20 Лексикон Фармасьютикалз, Инк. (Us) Полициклические соединения и способы их применения
WO2007044085A2 (en) 2005-05-19 2007-04-19 Xenon Pharmaceuticals Inc. Heteroaryl compounds and their uses as therapeutic agents
US8495335B2 (en) * 2006-06-16 2013-07-23 Raytheon Company Data translation system and method
KR20110026481A (ko) 2008-06-20 2011-03-15 메타볼렉스, 인코포레이티드 아릴 ｇｐｒ１１９ 작동약 및 이의 용도
PT2563776T (pt) 2010-04-27 2016-09-19 Calcimedica Inc Compostos que modulam o cálcio intracelular
WO2011143365A1 (en) * 2010-05-13 2011-11-17 Amgen Inc. Nitrogen heterocyclic compounds useful as pde10 inhibitors
CA2798325A1 (en) 2010-05-13 2011-11-17 Amgen Inc. Heteroaryloxyheterocyclyl compounds as pde10 inhibitors
US20120184572A1 (en) 2011-01-13 2012-07-19 Metabolex, Inc. Aryl gpr119 agonists and uses thereof
CA2853722A1 (en) * 2011-10-27 2013-05-02 Mayo Foundation For Medical Education And Research Inhibiting g protein coupled receptor 6 kinase polypeptides
WO2014028479A1 (en) 2012-08-13 2014-02-20 Envoy Therapeutics, Inc. Quinoxaline derivatives as gpr6 modulators
EP3060550B1 (en) 2013-10-21 2019-05-15 Merck Patent GmbH Heteroaryl compounds as btk inhibitors and uses thereof
MA39337B1 (fr) * 2014-02-14 2019-11-29 Takeda Pharmaceuticals Co Modulateurs de pyrazines de gpr6

Also Published As

Publication number Publication date
DOP2016000211A (es) 2016-10-16
MX2016010529A (es) 2016-10-31
MY184366A (en) 2021-04-01
MA39337A1 (fr) 2017-10-31
AU2015218402A1 (en) 2016-09-15
CN106103421A (zh) 2016-11-09
IL247140B (en) 2020-02-27
EP3105216B1 (en) 2018-10-10
PH12016501613B1 (en) 2021-10-01
GEAP201814266A (en) 2018-05-10
MA39337B1 (fr) 2019-11-29
ZA201606077B (en) 2018-11-28
EA033861B1 (ru) 2019-12-03
BR112016018418A2 (pt) 2017-08-08
UA117779C2 (uk) 2018-09-25
EP3105216A1 (en) 2016-12-21
PH12016501613A1 (en) 2017-02-06
JP2017509601A (ja) 2017-04-06
CA2939382A1 (en) 2015-08-20
IL247140A0 (en) 2016-09-29
KR20160122215A (ko) 2016-10-21
ES2702205T3 (es) 2019-02-27
GEP20186893B (en) 2018-09-10
US20180258073A1 (en) 2018-09-13
CN106103421B (zh) 2019-04-09
CR20160428A (es) 2017-04-04
US10273225B2 (en) 2019-04-30
EA201691632A1 (ru) 2017-02-28
US10000468B2 (en) 2018-06-19
PE20170245A1 (es) 2017-03-30
WO2015123533A1 (en) 2015-08-20
CL2016002043A1 (es) 2017-02-17
AU2015218402B2 (en) 2019-07-11
JP6484640B2 (ja) 2019-03-13
US20170174659A1 (en) 2017-06-22
MX369857B (es) 2019-11-25

Similar Documents

Publication Publication Date Title
UY35908A (es) Moduladores de tetrahidropiridopirazinas de gpr6
ECSP16073190A (es) Ciclopropilaminas como inhibidores de lsd1
DOP2018000008A (es) Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r)
UY36419A (es) Composiciones farmacéuticas que contienen anticuerpos anti-cd38 para el tratamiento de la leucemia mieloide aguda
CL2017003055A1 (es) Agonistas de receptor de apelina (apj) de 4-hidroxi-3-(heteroaril)piridin-2-ona para uso en el tratamiento de trastornos cardiovasculares.
DOP2017000120A (es) 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139
MX2017006283A (es) Peptidos macrociclicos utiles como inmunomoduladores.
CL2016002157A1 (es) Anticuerpos anti-cd38 para el tratamiento de leucemia linfoide aguda
ECSP16074207A (es) Pirazinas moduladoras de gpr6
ECSP15045801A (es) Inhibidores de la phd de 6–(5–hidroxi–1h–pirazol–1–il)nicotinamida
EA201992183A3 (ru) Синтез полициклических карбамоилпиридоновых соединений
ECSP18010535A (es) 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
MX2017005044A (es) Activador de canales de kcnq2-5.
UY36221A (es) Derivados de isoindolinona
MX2015010728A (es) Metodos y composiciones para el tratamiento de leucemia.
DOP2017000196A (es) Derivados de tetrahidropiranil benzamida
BR112016028698A2 (pt) preparação de piperidina-4-carbotioamida
MX2017011388A (es) Proceso para la preparacion de derivados de fenilisoxazolina sustituida.